BioCentury | Jan 29, 2020
Product Development

Decibel narrows discovery focus to inner ear regeneration, taps Reid as CEO

Under the leadership of incoming CEO Laurence Reid, hearing loss company Decibel is starting its next chapter in drug discovery with a narrowed focus on inner ear cell regeneration and programs in balance disorders. Reid...
BC Extra | Sep 16, 2019
Company News

Management tracks: Gottlieb joins FasterCures’ board; plus Foghorn, Varian

Former FDA Commissioner Scott Gottlieb has been appointed to the advisory board of FasterCures , a center of the Milken Institute dedicated to speeding up and improving medical research. Gottlieb stepped down from FDA's top post...
BC Extra | Aug 23, 2019
Company News

Management tracks: Erasca, Frequency, PerkinElmer, CytomX, Infinity and more

Erasca Inc. (San Diego, Calif.) promoted Chief Business Officer Gary Yeung to chief operating and financial officer and hired David Chacko to take over the CBO role. Chacko was a principal at investment firm Versant...
BC Extra | Jan 28, 2019
Company News

Management tracks: Ironwood reveals board for new companies

Ironwood Pharmaceuticals Inc. (NASDAQ:IRWD) named Mark Currie as incoming president of its spinout Cyclerion Therapeutics Inc. Currie will also join Ironwood's board following the separation, which is on track to occur this half. He is...
BC Extra | Jan 23, 2019
Company News

Vertex fires COO Smith for personal misconduct

Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) said Wednesday it has terminated COO and interim CFO Ian Smith due to "personal behavior that violated Vertex’s Code of Conduct and values and is unrelated to the Company’s financial and...
BioCentury | Jan 5, 2019
Finance

Ready to launch

  The proposed $74 billion takeout of Celgene Corp. by Bristol-Myers Squibb Co. will not shift buysider attention away from upcoming and maturing drug launches heading into 2019, with plenty to track following a record...
BC Week In Review | Oct 19, 2018
Financial News

Verastem raises $150M in notes offering

Verastem Inc. (NASDAQ:VSTM) raised $150 million on Oct. 11 through the sale of 5% convertible senior notes due 2048. The notes have an initial conversion price of about $7.16, which is a 14% premium to...
BioCentury | Oct 6, 2018
Finance

Large cap comeback

The biotech sector continued to be a stock pickers’ market through 3Q18 as there was a near even split between global biotech stocks that gained and lost value in the quarter. While 1H18 saw investors...
BC Week In Review | Sep 28, 2018
Company News

Verastem grants CSPC rights to Copiktra in China

Verastem Inc. (NASDAQ:VSTM) granted CSPC Pharmaceutical Group Ltd. (HKSE:1093) exclusive rights to develop and commercialize cancer drug Copiktra duvelisib in China, including Hong Kong and Macau, and Taiwan. The partners announced the deal on Sept....
BC Week In Review | Sep 28, 2018
Clinical News

FDA approves Verastem's duvelisib

FDA approved Copiktra duvelisib from Verastem Inc. (NASDAQ:VSTM) to treat relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) after at least two prior therapies. The agency also granted accelerated approval to...
Items per page:
1 - 10 of 357
BioCentury | Jan 29, 2020
Product Development

Decibel narrows discovery focus to inner ear regeneration, taps Reid as CEO

Under the leadership of incoming CEO Laurence Reid, hearing loss company Decibel is starting its next chapter in drug discovery with a narrowed focus on inner ear cell regeneration and programs in balance disorders. Reid...
BC Extra | Sep 16, 2019
Company News

Management tracks: Gottlieb joins FasterCures’ board; plus Foghorn, Varian

Former FDA Commissioner Scott Gottlieb has been appointed to the advisory board of FasterCures , a center of the Milken Institute dedicated to speeding up and improving medical research. Gottlieb stepped down from FDA's top post...
BC Extra | Aug 23, 2019
Company News

Management tracks: Erasca, Frequency, PerkinElmer, CytomX, Infinity and more

Erasca Inc. (San Diego, Calif.) promoted Chief Business Officer Gary Yeung to chief operating and financial officer and hired David Chacko to take over the CBO role. Chacko was a principal at investment firm Versant...
BC Extra | Jan 28, 2019
Company News

Management tracks: Ironwood reveals board for new companies

Ironwood Pharmaceuticals Inc. (NASDAQ:IRWD) named Mark Currie as incoming president of its spinout Cyclerion Therapeutics Inc. Currie will also join Ironwood's board following the separation, which is on track to occur this half. He is...
BC Extra | Jan 23, 2019
Company News

Vertex fires COO Smith for personal misconduct

Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) said Wednesday it has terminated COO and interim CFO Ian Smith due to "personal behavior that violated Vertex’s Code of Conduct and values and is unrelated to the Company’s financial and...
BioCentury | Jan 5, 2019
Finance

Ready to launch

  The proposed $74 billion takeout of Celgene Corp. by Bristol-Myers Squibb Co. will not shift buysider attention away from upcoming and maturing drug launches heading into 2019, with plenty to track following a record...
BC Week In Review | Oct 19, 2018
Financial News

Verastem raises $150M in notes offering

Verastem Inc. (NASDAQ:VSTM) raised $150 million on Oct. 11 through the sale of 5% convertible senior notes due 2048. The notes have an initial conversion price of about $7.16, which is a 14% premium to...
BioCentury | Oct 6, 2018
Finance

Large cap comeback

The biotech sector continued to be a stock pickers’ market through 3Q18 as there was a near even split between global biotech stocks that gained and lost value in the quarter. While 1H18 saw investors...
BC Week In Review | Sep 28, 2018
Company News

Verastem grants CSPC rights to Copiktra in China

Verastem Inc. (NASDAQ:VSTM) granted CSPC Pharmaceutical Group Ltd. (HKSE:1093) exclusive rights to develop and commercialize cancer drug Copiktra duvelisib in China, including Hong Kong and Macau, and Taiwan. The partners announced the deal on Sept....
BC Week In Review | Sep 28, 2018
Clinical News

FDA approves Verastem's duvelisib

FDA approved Copiktra duvelisib from Verastem Inc. (NASDAQ:VSTM) to treat relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) after at least two prior therapies. The agency also granted accelerated approval to...
Items per page:
1 - 10 of 357